Auro Vaccines LLC
Pearl River, NY
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 401 N Middletown Rd Bldg 205F, Pearl River, NY 10965, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$22,080 |
| FY2025 | $61,916 |
| FY2024 | $650,076 |
| FY2023 | $4,095,421 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Advanced development of multivalent vaccine candidates for filovirus and lassa fever | National Institute of Allergy and Infectious Diseases (NIH) | $10,706,003 |
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | HU00012220003 | $50,082 | |
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | U19AI142764 | $3,737,976 |
Similar vendors
About the company
Auro Vaccines LLC is a foreign owned, for-profit organization that provides vaccine development and manufacturing services to the U.S. government. Through prime federal contracts, Auro Vaccines conducts advanced development of multivalent vaccine candidates for filoviruses and Lassa fever. A $25.2 million contract was awarded in 2020 by the National Institute of Allergy and Infectious Diseases to support a six-year effort concluding in 2026 for vaccine development work performed in Baltimore, Maryland.
As a subcontractor under federal grants, Auro Vaccines has focused its vaccine development work on viral hemorrhagic fevers and henipaviruses. This includes constructing and testing recombinant vesicular stomatitis virus vectored vaccine candidates against Ebola virus species, Marburg virus, Crimean-Congo hemorrhagic fever virus, and Nipah and Hendra viruses. Prime grant partners have included the University of Texas Medical Branch at Galveston and The Henry M. Jackson Foundation for the Advancement of Military Medicine.
Through both prime contracts and subawards under federal grants, Auro Vaccines provides specialized services in viral vaccine construct development, immunogenicity and efficacy testing, and early stage manufacturing process development. Its work supports U.S. government efforts to effectively respond to emerging epidemic viral diseases as well as potential biological threats.
Quick answers
Is Auro Vaccines LLC registered in SAM.gov?
Yes. Auro Vaccines LLC's SAM.gov registration is active through March 13, 2027.
What is Auro Vaccines LLC's CAGE code?
Auro Vaccines LLC's CAGE code is 8EWB4, and its Unique Entity ID (UEI) is JCL5JKNMYAU5.
How much has Auro Vaccines LLC received in federal contracts?
Federal contracts obligated $61,916 to Auro Vaccines LLC in fiscal year 2025 and $4,785,333 in fiscal years 2023 through 2027.
What is Auro Vaccines LLC's most recent federal award?
Auro Vaccines LLC's most recent federal contract award is Advanced development of multivalent vaccine candidates for filovirus and lassa fever (75N93020C00040), from National Institute of Allergy and Infectious Diseases (NIH), on July 21, 2020.
On GovTribe
See Auro Vaccines LLC's full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors